Halozyme Therapeutics, Inc. (HALO)

業務介紹

Halozyme Therapeutics, Inc. 是一家位於美國、瑞士、愛爾蘭、比利時、日本和國際間的生物製藥技術平台公司。該公司的產品基於ENHANZE藥物傳遞技術，一種專利的重組人類透明質酸酶酶（rHuPH20），可實現注射生物製劑（如單克隆抗體和其他治療分子）、小分子和液體的皮下給藥。其旗艦產品是Hylenex重組，一種rHuPH20配方，用於促進皮下液體給藥，以增強皮下尿路攝影中其他注射藥物的分散和吸收，並改善放射性造影劑的吸收。該公司還開發了Perjeta；RITUXAN HYCELA和MabThera SC，用於非霍奇金淋巴瘤和慢性淋巴細胞白血病（CLL）的治療；RITUXAN SC用於CLL患者；以及HYQVIA用於免疫缺陷性疾病的治療。此外，該公司還正在開發Tecentriq用於非小細胞肺癌；OCREVUS用於多發性硬化症；DARZALEX用於治療淀粉樣變性、潛伏性骨髓瘤和多發性骨髓瘤的患者；nivolumab用於固體腫瘤的治療；ARGX-113，一種人類新生兒Fc受體；ARGX-117用於治療自身免疫性疾病；以及BMS-986179，一種抗CD-73抗體。該公司與F. Hoffmann-La Roche, Ltd.；Hoffmann-La Roche, Inc.；Baxalta US Inc.；Baxalta GmbH；Pfizer Inc.；Janssen Biotech, Inc.；AbbVie, Inc.；Eli Lilly and Company；Bristol-Myers Squibb Company；Alexion Pharma Holding；ARGENX BVBA；Horizon Therapeutics plc；National Institute of Allergy and Infectious Diseases；Centre for the AIDS Programme of Research in South Africa；以及ViiV Healthcare Limited合作，研究治療和預防HIV的小分子和大分子靶點。Halozyme Therapeutics, Inc.成立於1998年，總部位於加利福尼亞州聖地亞哥。

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

公司網址

https://www.halozyme.com